Latest contributions from John Wilding

Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

Editorial Board member John Wilding highlights the current evidence for the benefits of physical activity across various domains of type 2 diabetes care and prevention, presenting his view of what should be recommended.

Editorial Board member John Wilding examines what real-world data means to today’s clinicians and presents his vision for the future of this type of evidence.

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class (14:07).